Industry Survey Lays Bare Huge Disparities In Access To New Drugs In Europe
Executive Summary
A new survey has shown wide differences in patient access to new medicines across, and even within, European countries, with time to access after drug approval ranging from 100 to 1,000 days. Industry has put the blame on factors such as duplicative clinical assessments, the length of HTA processes, and local formulary decisions.
You may also be interested in...
‘Extreme Outlier’ Vertex Slammed For Orkambi Pricing Approach In England
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.